A theme involving the additional acquisition of Cullgen Series B preferred shares, increasing the ownership interest in Cullgen and Cullgen SH from 33.18% to 39.60%. The additional investment will strengthen involvement in and the investment stake in the drug discovery and pharmaceutical development business.